|
|
Simcere Takes Majority Stake in Rival Boda
publication date: Sep 28, 2007
Simcere Pharmaceutical of Nanjing paid 111 million RMB ($14.8 million) for a 51% stake in Boda Pharmaceutical, a company that markets a rival to Simcere’s best-selling drug, Bicun. Bicun, an injected edaravone, is a neuroprotective drug, administered following a stroke. Boda, which makes the only other injected edaravone available in China, has not released revenue figures, but Simcere said the company was “fast-growing.” More details...
Stock Symbol: (NYSE:SCR)
|
ChinaBio® Events
ChinaBio® Partnering Forum 2012May 23-24, 2012 Suzhou, China >>More events...
Partner Events
 China Healthcare Investment Conference 2012March 13-15, 2012 Shanghai, China Shanghai CEO ConferenceMarch 28-29, 2012 Shanghai, China >>More details...
Other Events
China Pharmaceutical R&D SummitApril 23-26, 2012 Shanghai, China Biosimilars Asia 2012April 23-26, 2012 Shanghai, China Vaccines China 2012April 23-26, 2012 Shanghai, China
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|